Peter Tarasoff

Learn More
BACKGROUND The new pyrimidine antimetabolite Gemcitabine has shown preclinical efficacy in a number of solid tumour lines and acceptable toxicity in phase I trials. As part of an ongoing effort to(More)
  • 1